Abstract
The article presents the results of a literature review devoted to the study of the problems of the concurrent course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), as well as chronic viral hepatitis (CVH) - chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The prevalence of CHB and CHC in IBD in different countries ranges from 1% to 9%. The clinical course of these concurrent diseases, the possibility of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation during immunosuppressive therapy are described. Recommendations on the peculiarities of examination and management of patients with concurrent pathology of IBD and CVH are presented. The combined pathology of IBD and CVH is a significant public health problem worldwide that requires further largescale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should occur on an individual basis.
Highlights
В статье представлены результаты обзора литературы, посвященного изучению проблем сочетанного течения воспалительных заболеваний кишечника (ВЗК), к которым относятся язвенный колит (ЯК) и болезнь Крона (БК), хронических вирусных гепатитов (ХВГ) – хронического гепатита В (ХГВ) и хронического гепатита С (ХГС)
The article presents the results of a literature review devoted to the study of the problems of the concurrent course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), as well as chronic viral hepatitis (CVH) - chronic hepatitis B (CHB) and chronic hepatitis C (CHC)
The prevalence of CHB and CHC in IBD in different countries ranges from 1% to 9%
Summary
В статье представлены результаты обзора литературы, посвященного изучению проблем сочетанного течения воспалительных заболеваний кишечника (ВЗК), к которым относятся язвенный колит (ЯК) и болезнь Крона (БК), хронических вирусных гепатитов (ХВГ) – хронического гепатита В (ХГВ) и хронического гепатита С (ХГС). Corresponding author: Volynets Galina, PhD, MD (Medicine), Professor; Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University; e-mail: volynec_g@mail.ru В последние годы были сообщения о риске реактивации вируса гепатита B (HBV) и вируса гепатита C (HCV) у пациентов, получающих иммуносупрессивную терапию [4, 5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
